Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Quinolinic acid lesion of the nigrostriatal pathway: effect on turning behaviour and protection by elevation of endogenous kynurenic acid in Rattus norvegicus
Autore:
Miranda, AF; Sutton, MA; Beninger, RJ; Jhamandas, K; Boegman, RJ;
Indirizzi:
Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada QueensUniv Kingston ON Canada K7L 3N6 icol, Kingston, ON K7L 3N6, Canada Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada Queens Univ Kingston ON Canada K7L 3N6 chol, Kingston, ON K7L 3N6, Canada Queens Univ, Dept Psychiat, Kingston, ON K7L 3N6, Canada Queens Univ Kingston ON Canada K7L 3N6 hiat, Kingston, ON K7L 3N6, Canada
Titolo Testata:
NEUROSCIENCE LETTERS
fascicolo: 2, volume: 262, anno: 1999,
pagine: 81 - 84
SICI:
0304-3940(19990305)262:2<81:QALOTN>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOPAMINERGIC-NEURONS; NICOTINYLALANINE INCREASES; PARKINSONS-DISEASE;
Keywords:
Parkinson's disease; quinolinic acid; kynurenic acid; substantia nigra; excitotoxicity; turning behaviour;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
16
Recensione:
Indirizzi per estratti:
Indirizzo: Boegman, RJ Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada Queens Univ Kingston ON Canada K7L 3N6 on, ON K7L 3N6, Canada
Citazione:
A.F. Miranda et al., "Quinolinic acid lesion of the nigrostriatal pathway: effect on turning behaviour and protection by elevation of endogenous kynurenic acid in Rattus norvegicus", NEUROSCI L, 262(2), 1999, pp. 81-84

Abstract

Endogenous excitotoxins have been implicated in degeneration of nigral dopaminergic neurons in Parkinson's disease. It may be possible to reduce neurodegeneration by blocking the effects of these endogenous agents. The present study shows that contralateral turning seen following quinolinic acid-induced lesions of the nigrostriatal dopaminergic pathway was reversed by a treatment that increased brain levels of kynurenic acid, an endogenous excitatory amino acid antagonist. The treatment consisted of nicotinylalanine (5.6 nmol/5 mu l i.c.v.), an inhibitor of kynureninase and kynurenine hydroxylase plus the precursor kynurenine (450 mg/kg i.p.) plus probenencid (200 mg/kg i.p.), an inhibitor of organic acid transport. Thus, neuroprotection by increasing brain kynurenic acid in vivo may be useful in retarding cell loss in Parkinson's and other neurodegenerative diseases involving excitotoxicity. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 11:20:49